



CONTACT:
Investor Relations
David Isserman
877-895-5647
IR@nutrapharma.com

**NUTRA PHARMA NAMES MICROBIOLOGIST AND FORMER INFECTECH
EXECUTIVE TO HEAD THE ADVISORY BOARD OF DESIGNER DIAGNOSTICS**

Boynton Beach, FL. – February 6, 2006 - Nutra Pharma Corp., (OTCBB: NPHC) a biotechnology company that owns rights to intellectual property related to the development of drugs for HIV and Multiple Sclerosis has announced that it has engaged Robert A Ollar, PhD to act as the Chairman of Designer Diagnostics' Scientific Advisory Board. Designer Diagnostics is the Company's new wholly-owned subsidiary created for the purpose of marketing diagnostic test kits designed for the rapid isolation and identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma acquired the rights to these diagnostic test kits in a definitive agreement signed with NanoLogix, Inc. (PinkSheets: NNLX).

Dr. Robert A Ollar is an internationally respected Microbiologist and Molecular Biologist with more than 30 years of experience in researching TB, Mycobacterial and Nocardial Diseases. His work has been granted more than 20 US and foreign patents. Dr. Ollar is an active member of the Global Stop TB Partnership and the TB Training and Educational Network for the Centers for Disease Control (CDC). Dr. Ollar also serves as a Foreign Advisor for Mycobacterial and Nocardial Diseases for the Mahatma Gandhi Institute, the Research Institute of Tropical Medicine, the COMSATS Institute of Information Technology and the Department of Biosciences in Islamabad, Pakistan.

Dr. Ollar also acts as an Assistant Professor of Neurology at New York Medical College (Valhalla, New York), and Lecturer on Infectious Diseases of the Central Nervous Systems in the Dept of Neurology, St. Vincent's Hospital and Medical Center of New York (New York, NY).

"Dr. Ollar is one of the original inventors of the technology used in the TestKits being marketed by Designer Diagnostics," said Rik J Deitsch, Nutra Pharma's Chief Executive Officer. "He will be instrumental in our sales and marketing efforts as we educate the global community on the necessity of using these diagnostic kits. His contacts in Asia and Africa will allow us to realize our first revenues by the second quarter of 2006," he added.

"I've been working with this technology for almost seventeen years," commented Dr. Robert A Ollar, Chairman of Designer Diagnostics' Scientific Advisory Board. "I'm looking forward to finally bringing this patented technology to the marketplace, especially to countries with the greatest need. Over 2 million people die from TB annually. Many of these deaths could be prevented with easy access to early detection and treatment. We are dedicated to helping in the worldwide effort to eradicate Tuberculosis and other deadly bacterial infectious diseases," he concluded.

About Nutra Pharma Corp.

Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's holding, ReceptoPharm, Inc, is developing technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

<http://www.nutrapharma.com>

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The information in this press release should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

###